Home Cart Sign in  
Chemical Structure| 187164-19-8 Chemical Structure| 187164-19-8

Structure of Luliconazole
CAS No.: 187164-19-8

Chemical Structure| 187164-19-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Luliconazole is a topical antifungal agent used to treat athlete's foot, jock itch, and ringworm caused by dermatophytes.

Synonyms: NND 502

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Luliconazole

CAS No. :187164-19-8
Formula : C14H9Cl2N3S2
M.W : 354.28
SMILES Code : N#C/C(N1C=CN=C1)=C2SC[C@@H](C3=CC=C(Cl)C=C3Cl)S/2
Synonyms :
NND 502
MDL No. :MFCD00953915
InChI Key :YTAOBBFIOAEMLL-REQDGWNSSA-N
Pubchem ID :3003141

Safety of Luliconazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Saprophytic fungi <0.0039 µg/mL 48 hours Evaluate the in vitro antifungal activity of Luliconazole against Saprophytic fungi, results showed that LUL was highly susceptible to Saprophytic fungi. Front Cell Infect Microbiol. 2021 Jul 15;11:693522
Dermatophytes <0.0039 µg/mL 48 hours Evaluate the in vitro antifungal activity of Luliconazole against Dermatophytes, results showed that LUL was highly susceptible to Dermatophytes. Front Cell Infect Microbiol. 2021 Jul 15;11:693522
Candida species 0.0125-2 µg/mL 48 hours Evaluate the in vitro antifungal activity of Luliconazole against Candida species, results showed that LUL was highly susceptible to Candida species. Front Cell Infect Microbiol. 2021 Jul 15;11:693522
Aspergillus fumigatus isolates 0.0004–0.25 mg/L 48 hours To determine the specific minimal inhibitory concentration (MIC) of LLCZ, showing MIC50 of 0.002 mg/L and MIC90 of 0.015 mg/L, with no significant differences between triazole-resistant and wild-type isolates. J Fungi (Basel). 2022 Mar 28;8(4):350
Trematosphaeria grisea 0.001–0.064 µg/ml 7 days Evaluate the in vitro inhibitory activity of Luliconazole against Trematosphaeria grisea, showing a median MIC of 0.064 µg/ml. Mycoses. 2022 Jun;65(6):650-655
Fusarium keratoplasticum 0.2 µg/mL 72 hours Evaluate the in vitro antifungal activity of Luliconazole against Fusarium keratoplasticum, showing significant growth inhibition in the 0-hour incubation group J Fungi (Basel). 2023 Sep 26;9(10):966
Aspergillus flavus 0.1 µg/mL 72 hours Evaluate the in vitro antifungal activity of Luliconazole against Aspergillus flavus, showing significant growth inhibition in the 0-hour incubation group J Fungi (Basel). 2023 Sep 26;9(10):966
Fusarium species 0.001 to 0.125 μg/ml 48 hours To evaluate the in vitro antifungal activity of Luliconazole against Fusarium species, showing very low MIC values indicating potent activity. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00009-18

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Albino Wistar rats Candida albicans infection model Topical application 25 mg/kg/day Once daily for 14 days To evaluate the antifungal activity of LZIVSopt-G3 against C. albicans infection, results showed significant inhibition of fungal infection by LZIVSopt-G3. Gels. 2023 Aug 3;9(8):626
Galleria mellonella (greater wax moth larvae) A. fumigatus-infected larvae model Injection 152 mg/L Single dose, monitored for 7 days Tested the therapeutic effect of LLCZ against ARAF infection, showing a significantly higher survival rate (41%) in treated larvae compared to the control group (21%). J Fungi (Basel). 2022 Mar 28;8(4):350
Porcine Corneal model Topical administration 0.1 µg/mL (A. flavus), 0.2 µg/mL (F. keratoplasticum) Medium change every 24 hours for 72 hours Evaluate the antifungal efficacy of Luliconazole in a porcine corneal model against A. flavus and F. keratoplasticum, showing significant growth inhibition in the 0-hour and 24-hour incubation groups but significantly reduced efficacy in the 48-hour incubation group J Fungi (Basel). 2023 Sep 26;9(10):966

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02767947 Tinea Corporis Phase 4 Completed - Dominican Republic ... More >> Valeant Site 03 San Cristobal, Dominican Republic, 91000 Valeant Site 01 Santo Domingo, Dominican Republic, 10700 Honduras Valeant Site 02 San Pedro Sula, Honduras, CT1100 Less <<
NCT00869336 Tinea Pedis Phase 2 Completed - United States, Minnesota ... More >> Fridley, Minnesota, United States, 55432 United States, Oregon Portland, Oregon, United States, 97210 United States, Texas Austin, Texas, United States, 78759 College Station, Texas, United States, 77840 Less <<
NCT01044381 Onychomycosis Phase 1 Phase 2 Completed - United States, Texas ... More >> J&S Studies College Station, Texas, United States, 77840 Less <<
NCT02394340 Tinea Pedis T... More >>inea Cruris Less << Phase 4 Unknown July 2015 United States, New Jersey ... More >> TKL Research Recruiting Fair Lawn, New Jersey, United States, 07410 Contact: Irina Krause, RN    201-587-0505    ikrause@tklresearch.com Less <<
NCT01431820 Distal and Lateral Subungual O... More >>nychomycosis Less << Phase 2 Phase 3 Completed - -
NCT02767271 Tinea Pedis T... More >>inea Cruris Less << Phase 4 Completed - Dominican Republic ... More >> Valeant Site 01 Santo Domingo, Dominican Republic, 10700 Honduras Valeant Site 02 San Pedro Sula, Honduras, CT1100 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.82mL

0.56mL

0.28mL

14.11mL

2.82mL

1.41mL

28.23mL

5.65mL

2.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories